Prevalence of antibiotics prescription amongst patients with and without COVID-19 in low- and middle-income countries: a systematic review and meta-analysis.

Yohanes Aditya Adhi Satria, Monica Suci Utami, Alexander Prasudi
Author Information
  1. Yohanes Aditya Adhi Satria: Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia. ORCID
  2. Monica Suci Utami: Undergraduate Program, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Sleman, Indonesia. ORCID
  3. Alexander Prasudi: Pratama Satria Health Clinic, Sleman, Indonesia.

Abstract

Antimicrobial resistance (AMR) poses a substantial risk to public health. In low-income and middle-income (LMICs) nations, the impact of AMR is significantly more severe. The absence of data from low-income countries (LMICs) causes this topic to be frequently overlooked. Additionally, the COVID-19 pandemic could make the AMR issue even worse. Earlier guidelines recommended antibiotic use in patients with COVID-19, even in those without bacterial coinfection. This study aims to investigate the proportion of antibiotic prescriptions in LMICs among patients with and without coronavirus disease-2019 (COVID-19), the proportion of inappropriate antibiotics, and multi-antibiotic prescribing. We followed the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA). We retrieved data through online databases, including PubMed, Scopus, and ScienceDirect. Amongst COVID-19 patients, the meta-analytic estimate of antibiotic prescription was 0.80 (95% CI: 0.72-0.88), whereas antibiotic use among patients with non-COVID-19 infections was 0.54 (95% CI: 0.49-0.58). Half of those prescribed antibiotics (0.52, 95% CI: 0.32-0.72) are inappropriate prescriptions. In addition, we found that one-third of antibiotics prescriptions consisted of more than one antibiotic (0.32, 95% CI: 0.21-0.43). In conclusion, antibiotics are highly prescribed across LMICs, and their use is increased in patients with COVID-19. Amongst those prescriptions, inappropriate and multiple use was not uncommon. This study has several limitations, as it included two studies in an ambulatory setting, and some of the studies included in the analysis were conducted on a small scale. Nevertheless, our findings suggest that urgent action to improve prescribing practices is essential.

Keywords

References

  1. PLoS One. 2019 Sep 26;14(9):e0222651 [PMID: 31557170]
  2. Crit Care. 2020 Apr 30;24(1):188 [PMID: 32354360]
  3. Int J Clin Pract. 2021 Jun;75(6):e14113 [PMID: 33629481]
  4. Am J Trop Med Hyg. 2018 Jun;98(6):1571-1576 [PMID: 29714159]
  5. BMC Public Health. 2019 Jun 21;19(1):797 [PMID: 31226974]
  6. Int J Prev Med. 2015 Jan 15;6:1 [PMID: 25789136]
  7. Arch Dis Child. 2015 Oct;100(10):966-9 [PMID: 25994002]
  8. Lancet Reg Health West Pac. 2021 Nov 03;18:100306 [PMID: 35024650]
  9. J Infect Public Health. 2017 Jan - Feb;10(1):41-48 [PMID: 26952648]
  10. N Engl J Med. 2020 May 7;382(19):1787-1799 [PMID: 32187464]
  11. Interdiscip Perspect Infect Dis. 2018 Feb 28;2018:4323769 [PMID: 29681933]
  12. Trans R Soc Trop Med Hyg. 2019 Nov 1;113(11):714-721 [PMID: 31294806]
  13. NPJ Prim Care Respir Med. 2016 Jan 14;26:15076 [PMID: 26769226]
  14. Trop Med Health. 2019 Jul 18;47:45 [PMID: 31360099]
  15. Antimicrob Resist Infect Control. 2017 Apr 28;6:41 [PMID: 28465825]
  16. J Glob Antimicrob Resist. 2019 Dec;19:201-206 [PMID: 31077858]
  17. JAMA. 2020 Mar 17;323(11):1061-1069 [PMID: 32031570]
  18. Arch Iran Med. 2016 Mar;19(3):204-9 [PMID: 26923893]
  19. J Multidiscip Healthc. 2013 Aug 20;6:303-10 [PMID: 23990728]
  20. Turk J Med Sci. 2020 Sep 15;51(2):523-529 [PMID: 32927931]
  21. N Engl J Med. 2020 Apr 30;382(18):1708-1720 [PMID: 32109013]
  22. Drugs Real World Outcomes. 2016 Sep;3(3):327-332 [PMID: 27747832]
  23. Lancet. 2022 Feb 12;399(10325):629-655 [PMID: 35065702]
  24. JAMA Intern Med. 2014 Dec;174(12):1914-20 [PMID: 25285394]
  25. Lancet. 2020 Mar 28;395(10229):1054-1062 [PMID: 32171076]
  26. Turk Pediatri Ars. 2018 Mar 01;53(1):17-23 [PMID: 30083070]
  27. Antibiotics (Basel). 2021 Feb 09;10(2): [PMID: 33572240]
  28. Infect Control Hosp Epidemiol. 2020 Aug;41(8):982-983 [PMID: 32279676]
  29. Antimicrob Resist Infect Control. 2019 Aug 7;8:132 [PMID: 31406571]
  30. Antibiotics (Basel). 2022 May 30;11(6): [PMID: 35740140]
  31. Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3463-E3470 [PMID: 29581252]
  32. J Clin Epidemiol. 2012 Sep;65(9):934-9 [PMID: 22742910]
  33. Antimicrob Resist Infect Control. 2018 Jul 16;7:82 [PMID: 30026940]
  34. Explor Res Clin Soc Pharm. 2022 Mar;5:100101 [PMID: 34977851]
  35. BMJ Glob Health. 2019 Nov 10;4(6):e002104 [PMID: 31799007]
  36. Health Policy Plan. 2016 Mar;31(2):250-8 [PMID: 26045328]
  37. Glob Health Action. 2017;10(1):1287334 [PMID: 28462635]
  38. Afr Health Sci. 2018 Dec;18(4):1189-1201 [PMID: 30766585]
  39. Int J Infect Dis. 2018 Jun;71:20-24 [PMID: 29608958]
  40. Int Health. 2017 Mar 1;9(2):124-130 [PMID: 28338813]
  41. Antibiotics (Basel). 2022 Jan 09;11(1): [PMID: 35052951]
  42. Int J Clin Pract. 2017 Dec;71(12): [PMID: 29178350]
  43. Int J Clin Pract. 2021 Nov;75(11):e14740 [PMID: 34403534]
  44. BMC Health Serv Res. 2017 Jan 5;17(1):10 [PMID: 28056949]
  45. J Infect Dev Ctries. 2020 Jan 31;14(1):18-27 [PMID: 32088680]
  46. Pak J Med Sci. 2014 May;30(3):462-5 [PMID: 24948959]
  47. Lancet Infect Dis. 2020 Feb;20(2):179-187 [PMID: 31843383]
  48. BMJ. 2020 Mar 26;368:m1091 [PMID: 32217556]
  49. Clin Microbiol Infect. 2020 Dec;26(12):1622-1629 [PMID: 32711058]
  50. Drug Healthc Patient Saf. 2019 Feb 08;11:1-5 [PMID: 30799958]
  51. S Afr Med J. 2018 Mar 28;108(4):304-310 [PMID: 29629681]
  52. Int J Gen Med. 2022 Apr 01;15:3591-3603 [PMID: 35392031]
  53. J Family Med Prim Care. 2022 Feb;11(2):503-511 [PMID: 35360769]
  54. Pharmacoepidemiol Drug Saf. 2021 Sep;30(9):1242-1249 [PMID: 34155708]
  55. J Clin Diagn Res. 2016 Nov;10(11):FC05-FC08 [PMID: 28050392]
  56. Lancet. 2016 Jan 9;387(10014):168-75 [PMID: 26603918]
  57. PLoS One. 2018 Mar 5;13(3):e0193353 [PMID: 29505584]
  58. BMC Pharmacol Toxicol. 2015 Mar 31;16:6 [PMID: 25884702]
  59. Trop Med Health. 2021 Jun 23;49(1):51 [PMID: 34162445]
  60. Balkan Med J. 2022 May 24;39(3):209-217 [PMID: 35611705]
  61. Antibiotics (Basel). 2021 Dec 14;10(12): [PMID: 34943740]
  62. J Trop Pediatr. 2021 Jul 2;67(3): [PMID: 33221898]
  63. Antibiotics (Basel). 2020 Aug 09;9(8): [PMID: 32784880]
  64. Expert Rev Anti Infect Ther. 2021 Aug;19(8):1047-1051 [PMID: 33307895]
  65. P T. 2015 Apr;40(4):277-83 [PMID: 25859123]
  66. Pediatr Int. 2020 Jun;62(6):683-687 [PMID: 31957141]
  67. BMC Pharmacol Toxicol. 2018 Jul 27;19(1):46 [PMID: 30049281]
  68. Expert Rev Anti Infect Ther. 2022 Feb;20(2):147-160 [PMID: 34225545]
  69. BMC Public Health. 2017 Nov 28;17(1):908 [PMID: 29183293]
  70. BMC Infect Dis. 2020 Jan 30;20(1):86 [PMID: 32000722]
  71. Trop Med Int Health. 2015 Dec;20(12):1696-706 [PMID: 26311240]
  72. Public Health Action. 2014 Dec 21;4(4):259-64 [PMID: 26400706]
  73. BMC Infect Dis. 2018 Sep 29;18(1):492 [PMID: 30268106]
  74. Int J Clin Pharm. 2017 Aug;39(4):913-918 [PMID: 28626850]
  75. Rural Remote Health. 2019 Jun;19(2):4818 [PMID: 31200600]
  76. Lancet Respir Med. 2020 May;8(5):475-481 [PMID: 32105632]
  77. Infect Prev Pract. 2021 Jul 24;3(3):100163 [PMID: 34430842]
  78. BMJ Open. 2018 Jul 30;8(7):e022250 [PMID: 30061442]
  79. PLoS One. 2019 Aug 5;14(8):e0219097 [PMID: 31381611]
  80. Antibiotics (Basel). 2021 Feb 18;10(2): [PMID: 33670731]
  81. Implement Sci. 2022 May 12;17(1):30 [PMID: 35550169]
  82. BMC Infect Dis. 2016 May 17;16:208 [PMID: 27188538]

MeSH Term

Prevalence
Humans
COVID-19
Anti-Bacterial Agents
Developing Countries
Prescriptions
Inappropriate Prescribing

Chemicals

Anti-Bacterial Agents

Word Cloud

Created with Highcharts 10.0.00COVID-19patientsantibioticantibioticsLMICsuseprescriptions95%CI:AMRlow-incomemiddle-incomecountrieswithoutinappropriateprescriptionresistancedataevenstudyproportionamongprescribingAmongstprescribedincludedstudiesAntimicrobialposessubstantialriskpublichealthnationsimpactsignificantlysevereabsencecausestopicfrequentlyoverlookedAdditionallypandemicmakeissueworseEarlierguidelinesrecommendedbacterialcoinfectionaimsinvestigatecoronavirusdisease-2019multi-antibioticfollowedPreferredReportingItemsSystematicReviewMeta-analysisPRISMAretrievedonlinedatabasesincludingPubMedScopusScienceDirectmeta-analyticestimate8072-088whereasnon-COVID-19infections5449-058Half5232-072additionfoundone-thirdconsistedone3221-043conclusionhighlyacrossincreasedmultipleuncommonseverallimitationstwoambulatorysettinganalysisconductedsmallscaleNeverthelessfindingssuggesturgentactionimprovepracticesessentialPrevalenceamongstlow-countries:systematicreviewmeta-analysisAntibioticantimicrobial

Similar Articles

Cited By